Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (4003)	6/5/2001 10:20:15 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

I also thought that GZTC mAb production has solid fundamental. However, how management handled lead compound leave me with cold feet. It will take time before they get worm. Miljenko

To: Spekulatius who wrote (4003)	6/6/2001 12:49:14 AM
From: scaram(o)uche	Respond to of 52153

GZTC may have the most economical way to do that, IMO. Ralf: I own a small chunk of this company.......... Tuesday June 5, 8:50 am Eastern Time Press Release Epicyte Receives SBIR Grant to Fund HPV Antibody Development Marks Fifth Grant for Epicyte to Develop Sexual Health Products SAN DIEGO--(BW HealthWire)--June 5, 2001--Epicyte Pharmaceutical Inc. today announced that the Company has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health for the development of antibodies to prevent the transmission of human papillomavirus (HPV). The SBIR Advanced Technology grant, valued at $500,000, will help fund Epicyte's product development and clinical trials for an anti-viral topical microbicide to prevent the sexual transmission of pathogens. The product will be developed using Epicyte's Plantibodies(TM) technology for manufacturing human monoclonal antibodies in plants. (snip) biz.yahoo.com All other things equal (they aren't!), I'd bet on plants over milk. Keep your head up? If you start to see that GZTC, like Epicyte, is most enthusiastic about topical applications...... run, don't walk, away. In the interim, I'll share your enthusiasm for GZTC. However, the ATIII story is/was ugly.